- Global Pharma News & Resources

Global Human Microbiome Therapeutics Market Report 2021-2025: Market is Poised to Grow by $500+ Million, at a CAGR of 47.79% -

DUBLIN--(BUSINESS WIRE)--The "Global Human Microbiome Therapeutics Market 2021-2025" report has been added to's offering.

The human microbiome therapeutics market is poised to grow by $516.08 mn during 2021-2025, progressing at a CAGR of 47.79%

This study identifies the side effects of existing treatment as one of the prime reasons driving the human microbiome therapeutics market growth during the next few years. The market is driven by the growing prevalence of chronic diseases and robust pipeline.

The report on the human microbiome therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The human microbiome therapeutics market analysis includes the application segment and geographic landscape.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading human microbiome therapeutics market vendors that include 4D pharma Plc, ENTEROME SA, Ferring B.V., Johnson and Johnson Inc., Kaleido Biosciences Inc., OptiBiotix Health Plc, PureTech Health Plc, Second Genome Therapeutics, Seres Therapeutics Inc., and Takeda Pharmaceutical Co. Ltd.

Also, the human microbiome therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Key Topics Covered:

Executive Summary

  • Market overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2020
  • Market outlook: Forecast for 2020 - 2025

Five Forces Analysis

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Application

  • Market segments
  • Comparison by Application
  • Gastrointestinal disorders - Market size and forecast 2020-2025
  • Infectious diseases - Market size and forecast 2020-2025
  • Others - Market size and forecast 2020-2025
  • Market opportunity by Application

Customer landscape

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2020-2025
  • Europe - Market size and forecast 2020-2025
  • Asia - Market size and forecast 2020-2025
  • ROW - Market size and forecast 2020-2025
  • Key leading countries
  • Market opportunity By Geographical Landscape
  • Market drivers
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • 4D pharma Plc
  • Ferring B.V.
  • Johnson and Johnson Inc.
  • Kaleido Biosciences Inc.
  • OptiBiotix Health Plc
  • PureTech Health Plc
  • Second Genome Therapeutics
  • Seres Therapeutics Inc.
  • Takeda Pharmaceutical Co. Ltd

For more information about this report visit

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 02-Dec-2021